首页> 外文期刊>Cardiovascular toxicology >When Manual Analysis of 12-Lead ECG Holter Plays a Critical Role in Discovering Unknown Patterns of Increased Arrhythmogenic Risk: A Case Report of a Patient Treated with Tamoxifen and Subsequent Pneumonia in COVID-19
【24h】

When Manual Analysis of 12-Lead ECG Holter Plays a Critical Role in Discovering Unknown Patterns of Increased Arrhythmogenic Risk: A Case Report of a Patient Treated with Tamoxifen and Subsequent Pneumonia in COVID-19

机译:当12铅ECG HOLTER的手动分析发挥着关键作用时,在发现血淋力发生的未知模式方面发挥着关键作用:在Covid-19中用他莫昔芬和随后的肺炎治疗的患者的病例报告

获取原文
获取原文并翻译 | 示例
           

摘要

Several medicines, including cancer therapies, are known to alter the electrophysiological function of ventricular myocytes resulting in abnormal prolongation and dispersion of ventricular repolarization (quantified by multi-lead QTc measurement). This effect could be amplified by other concomitant factors (e.g., combination with other drugs affecting the QT, and/or electrolyte abnormalities, such as especially hypokalemia, hypomagnesaemia, and hypocalcemia). Usually, this condition results in higher risk of torsade de point and other life-threatening arrhythmias, related to unrecognized unpaired cardiac ventricular repolarization reserve (VRR). Being VRR a dynamic phenomenon, QT prolongation might often not be identified during the 10-s standard 12-lead ECG recording at rest, leaving the patient at increased risk for life-threatening event. We report the case of a 49-year woman, undergoing tamoxifen therapy for breast cancer, which alteration of ventricular repolarization reserve, persisting also after correction of concomitant recurrent hypokalemia, was evidenced only after manual measurements of the corrected QT (QTc) interval from selected intervals of the 12-lead ECG Holter monitoring. This otherwise missed finding was fundamental to drive the discontinuation of tamoxifen, shifting to another "safer" therapeutic option, and to avoid the use of potentially arrhythmogenic antibiotics when treating a bilateral pneumonia in recent COVID-19.
机译:已知包括癌症治疗在内的几种药物可改变心室肌细胞的电生理功能,导致心室复极异常延长和分散(通过多导联QTc测量量化)。其他伴随因素(例如,与影响QT的其他药物联合使用,和/或电解质异常,尤其是低钾血症、低镁血症和低钙血症)可能会放大这种效应。通常情况下,这种情况会导致与未识别的未配对心室复极储备(VRR)有关的尖端扭转型室性心动过速和其他危及生命的心律失常的风险增加。由于VRR是一种动态现象,在静息状态下进行10秒标准12导联心电图记录时,QT间期延长可能往往无法确定,从而增加患者发生危及生命事件的风险。我们报告了一例49岁女性乳腺癌患者接受他莫昔芬治疗,其心室复极储备的改变,在纠正伴随的复发性低钾血症后也持续存在,仅在从12导联心电图Holter监测的选定间隔手动测量校正QT(QTc)间隔后才得到证实。2019冠状病毒疾病的一种双侧肺炎,在另一种“安全”治疗方案中,这种缺失的发现是根本性的,并转移到另一种“更安全”的治疗方案中,避免使用潜在致心律失常的抗生素。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号